The latest news: Retroviral replicating vector–mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity Toca 511 is an experimental gene therapy being tested for recurrent glioblastoma. This study shows long lasting immunity - actually a cure - in mice. Even when they tried to inject a new tumor into these mice, the mice rejected the tumor. Tocagen wins "Most Successful Early Phase Trial" and "Excellence in Rare Disease Drug Development" awards! I am proud to say that the Musella Foundation has supported the development of this treatment with $130,000 in grants over the last 5 years. Winning the "Most Successful Early Phase Trial" is really impressive when you consider this is across all cancer types, not just brain tumors. Congratulations to Tocagen! Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. This is the second recent study to suggest that 6 months of Temozolomide might be optimal. However, this was not a randomized prospective trial. I would think each case is different and if things are going well, it may be worth using Temozolomide longer. If not, try something else. BrainTumor Co-Payment Assistance Program Status: CLOSED to new applicants
